DUBLIN--(BUSINESS WIRE)--The "Diabetic Macular Edema - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2020, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.
Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.
The Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 19, 15, 5, 50, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Diabetic Macular Edema - Overview
- Diabetic Macular Edema - Therapeutics Development
- Diabetic Macular Edema - Therapeutics Assessment
- Diabetic Macular Edema - Companies Involved in Therapeutics Development
- Diabetic Macular Edema - Drug Profiles
- Diabetic Macular Edema - Dormant Projects
- Diabetic Macular Edema - Discontinued Products
- Diabetic Macular Edema - Product Development Milestones
- 3SBio Inc
- Abpro Corp
- Aciont Inc
- Acucela Inc
- Aerie Pharmaceuticals Inc
- Aerpio Pharmaceuticals Inc
- Aldeyra Therapeutics Inc
- Allegro Ophthalmics LLC
- Allergan Plc
- Allgenesis Biotherapeutics Inc
- Ampio Pharmaceuticals Inc
- Apexian Pharmaceuticals Inc
- Araim Pharmaceuticals Inc
- Ascentage Pharma Group International
- AsclepiX Therapeutics Inc
- BetaStem Therapeutics Inc
- Bio-Thera Solutions Ltd
- Boehringer Ingelheim International GmbH
- Cell Care Therapeutics Inc
- Cell Medica Ltd
- Celon Pharma SA
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Chiome Bioscience Inc
- Clearside BioMedical Inc
- Coherus BioSciences Inc
- Elasmogen Ltd
- Eleusis Ltd
- Everglades Biopharma LLC
- Exonate Ltd
- EyeGate Pharmaceuticals Inc
- Eyevensys SAS
- F. Hoffmann-La Roche Ltd
- Formycon AG
- Gene Signal International SA
- Graybug Vision Inc
- Isarna Therapeutics GmbH
- Kalvista Pharmaceuticals Inc
- Kodiak Sciences Inc
- Kowa Co Ltd
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabion SA
- Momenta Pharmaceuticals Inc
- NeuBase Therapeutics Inc
- NeuMedics Inc
- Novartis AG
- Novelty Nobility Inc
- OccuRx Pty Ltd
- Ocugen Inc
- Ocular Therapeutix Inc
- Oculis SA
- OcuNexus Therapeutics Inc
- Opthea Ltd
- Outlook Therapeutics Inc
- Oxurion NV
- Pfizer Inc
- Phanes Therapeutics Inc
- PharmAbcine Inc
- Pleryon Therapeutics Ltd
- Protheragen Inc
- Qilu Pharmaceutical Co Ltd
- RemeGen Ltd
- Rezolute Inc
- RiniSight Inc
- SciFluor Life Sciences LLC
- Semathera Inc
- Senju Pharmaceutical Co Ltd
- Suzhou Stainwei Biotech Inc
- Targeted Therapy Technologies LLC
- Theravance Biopharma Inc
- Verseon Corp
- Xbrane Biopharma AB
- YD Life Science Co
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lrmhy2